Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Baricitinib by Eli Lilly and Co for Focal Segmental Glomerulosclerosis (FSGS): Likelihood of Approval
Baricitinib is under clinical development by Eli Lilly and Co and currently in Phase II for Focal Segmental Glomerulosclerosis (FSGS)....
Baricitinib by Eli Lilly and Co for Erosive Oral Lichen Planus: Likelihood of Approval
Baricitinib is under clinical development by Eli Lilly and Co and currently in Phase II for Erosive Oral Lichen Planus....
Baricitinib by Eli Lilly and Co for Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease): Likelihood of Approval
Baricitinib is under clinical development by Eli Lilly and Co and currently in Phase III for Systemic-Onset Juvenile Idiopathic Arthritis...
Baricitinib by Eli Lilly and Co for Juvenile Arthritis: Likelihood of Approval
Baricitinib is under clinical development by Eli Lilly and Co and currently in Phase III for Juvenile Arthritis. According to...
Baricitinib by Eli Lilly and Co for Polymyalgia Rheumatica (PMR): Likelihood of Approval
Baricitinib is under clinical development by Eli Lilly and Co and currently in Phase II for Polymyalgia Rheumatica (PMR). According...